Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

Prostate cancer has distinct genetic properties in different groups of men that could be targeted to improve patient outcomes ...

Scientists at the University of Michigan Rogel Cancer Center have found a promising new way to fight one of the most ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

The pre-analytical workflow is one of the primary considerations in the successful use of liquid biopsies for cancer ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy. Find an average timeline here.

Right now, there are more than 250 generic drugs on the market that show potential for fighting cancer, even though they were ...

Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each ...

They are more prone to metastasis and drug resistance ... chimeric RNAs in different cell types within cancer." Precise Prostate Cancer Treatment The new findings offer important insights into ...

Clinicians worldwide regard (Pluvicto) as a significant breakthrough therapy for patients with advanced disease' ...

They are more prone to metastasis and drug resistance ... to develop more tailored – and more effective – prostate cancer treatments. Further, chimeric RNA isn’t just found in prostate ...